Patients and surviving family members are filing lawsuits against Eli Lilly for not warning people about the dangers of Mounjaro
Improved Insulin Sensitivity and Blood Sugar Control By mimicking the GLP-1 hormone, this medication enhances the bodys response to insulin and helps maintain lower fasting blood glucose levels
Therefore, it will likely get full approval in 6 months (by summer of 2023) for weight loss in overweight/obese non-diabetic patients as we already have solid evidence of tackling the problem with GLP-1 receptor agonists
Tirzepatide is a GIP/GLP-1 dual agonist, engaging two receptor pathways, while semaglutide is a single-target GLP-1 receptor agonist
Side effects like blurred vision, change in vision, and slurred speech are also possible, although less common
10.1128/jvi.74.24.11782-11791.2000 318 ZimmerB.EwaleifohO.HarschnitzO.LeeY.PeneauC.McAlpineJ